Advancements and challenges in immunocytokines: A new arsenal against cancer
文献类型：期刊论文
| 作者 | Shi, Wenqiang1,3; Liu, Nan2; Lu, Huili1,3 |
| 刊名 | ACTA PHARMACEUTICA SINICA B
 |
| 出版日期 | 2024-11-01 |
| 卷号 | 14期号:11页码:4649-4664 |
| 关键词 | Bifunctional fusion Combination therapy Tumor-conditional Prodrug |
| ISSN号 | 2211-3835 |
| DOI | 10.1016/j.apsb.2024.07.024 |
| 通讯作者 | Lu, Huili(roadeer@sjtu.edu.cn) |
| 英文摘要 | Immunocytokines, employing targeted antibodies to concentrate cytokines at tumor sites, have shown potential advantages such as prolonged cytokine half-lives, mitigated adverse effects, and synergistic antitumor efficacy from both antibody and cytokine components. First, we present an indepth analysis of the advancements of immunocytokines evaluated in preclinical and clinical applications. Notably, anti-PD-1-based immunocytokines can redirect cytokines to intratumoral CD8 & thorn; T cells and reinvigorate them to elicit robust antitumor immune responses. Then, we focus on their molecular structures and action mechanisms, striving to elucidate the correlations between diverse molecular structures and their antitumor efficacy. Moreover, our exploration extends to the realm of novel cytokines, including IL-10, IL-18, and IL-24, unraveling their potential in the construction of immunocytokines. However, safety concerns remain substantial barriers to immunocytokines' development. To address this challenge, we explore potential strategies, such as cytokine engineering and prodrug design, which can foster next-generation immunocytokines development. Overall, this review concentrates on the design of molecular structures in immunocytokines, underscoring the direction and focus of ongoing efforts to improve safety profiles while maximizing therapeutic efficacy. |
| WOS关键词 | CYTOKINE FUSION PROTEINS ; PHASE-I TRIAL ; TGF-BETA ; ANTIBODY FRAGMENT ; TARGETED DELIVERY ; TUMOR-IMMUNITY ; NK CELLS ; HLA-DR ; INTERLEUKIN-12 ; COMBINATION |
| 资助项目 | Natural Science Foundation of Chongqing[2022NSCQ-MSX2319] ; Science & Technology Commission of Shanghai Municipality[21S11906300] ; Science & Technology Commission of Shanghai Municipality[23ZR1431800] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001363664500001 |
| 出版者 | INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/314689]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Lu, Huili |
| 作者单位 | 1.Shanghai Jiao Tong Univ, Sch Pharm, Engn Res Ctr Cell & Therapeut Antibody, Minist Educ, Shanghai 200240, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 3.Shanghai Jiao Tong Univ, Sch Pharm, Shanghai Frontiers Sci Ctr Drug Target Identificat, Natl Key Lab Innovat Immunotherapy, Shanghai 200240, Peoples R China |
| 推荐引用方式 GB/T 7714 | Shi, Wenqiang,Liu, Nan,Lu, Huili. Advancements and challenges in immunocytokines: A new arsenal against cancer[J]. ACTA PHARMACEUTICA SINICA B,2024,14(11):4649-4664. |
| APA | Shi, Wenqiang,Liu, Nan,&Lu, Huili.(2024).Advancements and challenges in immunocytokines: A new arsenal against cancer.ACTA PHARMACEUTICA SINICA B,14(11),4649-4664. |
| MLA | Shi, Wenqiang,et al."Advancements and challenges in immunocytokines: A new arsenal against cancer".ACTA PHARMACEUTICA SINICA B 14.11(2024):4649-4664. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。